Standard BioTools faces significant structural challenges as evidenced by a 48.2% revenue contraction in 2026Q1 and persistent operating losses, with an operating margin of -59.1%. While the company has successfully reduced total debt to $29.5M from $98.2M in ...
Price trend, volume and key moving averages
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 5, 2026 | -$0.07-449.0% vs -$0.01 | $20M-3.4% vs $21M |
Q2 2026 May 5, 2026 | -$0.02+0.0% vs -$0.02 | $21M+18.8% vs $18M |
Q1 2026 Feb 24, 2026 | $0.06+300.0% vs -$0.03 | $24M+28.6% vs $19M |
Q4 2025 Nov 4, 2025 | -$0.09-107.7% vs -$0.04 | $20M+8.6% vs $18M |
Standard BioTools Enters into New Purchase Agreement with Element Biosystems, a Subsidiary of GMT Venture, After Determining GMT Venture's Unsolicited Acquisition Proposal as Superior Standard BioTools Enters into New Purchase Agreement with Element Biosystems, a Subsidiary of GMT Venture, After Determining GMT Venture's Unsolicited Acquisition Proposal as Superior
Are SMTI, LAB, ATKR, VAL Obtaining Fair Deals for their Shareholders?PR NewswireNEW YORK, Sept. 11, 2026Insiders may stand to receive substantial financial bene
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
BOSTON, Mass. , Aug. 05, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the "Company" or "Standard BioTools") today announced financial results for the quarter ended June 30, 2026. Recent Highlights: Second quarter 2026 revenue of $20.
Benchmark LAB against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Standard BioTools Inc. (LAB)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.74 | $291.52M | -3.72 | -51.08% | -87.77% | -16.72% | — | |
| $38.75 | $1.79B | -31.76 | 3.55% | -20.02% | -7.56% | — | |
| $410.35 | $58.77B | -269.97 | 35.9% | -7.11% | -11.73% | — | |
| $2.54 | $788.93M | -1.40 | 3.89% | -82.49% | -4961.74% | — | |
| $2.25 | $123.71M | -1.76 | 15.57% | -490.71% | -27.23% | — | |
| $67.15 | $3.47B | -167.88 | 13.79% | 24.23% | 32.81% | — |
Standard BioTools Inc. (LAB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Standard BioTools Inc. (LAB) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
Jul 28, 2026·SEC
Jul 24, 2026·SEC
Get notified when LAB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Standard BioTools Inc. (LAB) stock FAQ — growth, dividends, profitability & financials explained
Standard BioTools Inc. (LAB) reported $84.6M in revenue for fiscal year 2025. This represents a 1222% increase from $6.4M in 2006.
Standard BioTools Inc. (LAB) saw revenue decline by 51.1% over the past year.
Standard BioTools Inc. (LAB) reported a net loss of $87.4M for fiscal year 2025.
Standard BioTools Inc. (LAB) has a return on equity (ROE) of -16.7%. Negative ROE indicates the company is unprofitable.
Standard BioTools Inc. (LAB) had negative free cash flow of $129.8M in fiscal year 2025, likely due to heavy capital investments.
